Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101)

NCT05387265 is registered in ClinicalTrials.gov with CytomX Therapeutics as lead sponsor.

NCT NCT05387265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101)
Lead sponsor
CytomX Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 16, 2022
Completion date
June 4, 2025
Enrollment
83 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors